Allinky Biopharma
Development of new drugs for the treatment of neurodegenerative diseases and chronic inflammation
Allinky Biopharma is an academic spin-off dedicated to the discovery and development of drugs for the treatment of pathologies related to chronic inflammation, cellular aging, and cancer.
Scientific and clinical experimentation has demonstrated the important role that oxidative stress, chronic inflammation, and dysregulation in cellular progression play in favoring the onset and evolution of diseases.
Allinky develops new drugs capable of modulating the abnormal molecular signals responsible for these diseases and, therefore, contributing to restore normal cellular gene expression.
The discovery of small molecules (new atomic compounds) and their latest medical, pharmaceutical, and biological research are proving crucial for the treatment of chronic inflammatory diseases and age-related degenerative diseases and cancer (treatment of chronic obstructive pulmonary disease, Alzheimer’s, and colorectal and pancreatic cancers).